טוען...
The Diversity of Biosimilar Design and Development: Implications for Policies and Stakeholders
Biosimilars are required to be similar or highly similar in structure to their biologic reference product but are neither expected nor required to contain identical active substances. For example, glycosylated biosimilars approved to date demonstrate quantitative and qualitative structural differenc...
שמור ב:
| הוצא לאור ב: | BioDrugs |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer International Publishing
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4684584/ https://ncbi.nlm.nih.gov/pubmed/26581551 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-015-0147-0 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|